NICE backs AZ’s Calquence for new use in leukaemiaAstraZeneca’s BTK inhibitor Calquence has become the first targeted oral therapy to be backed by NICE for NHS Share XNICE backs AZ’s Calquence for new use in leukaemiahttps://pharmaphorum.com/news/nice-backs-azs-calquence-for-new-use-in-leukaemia/
Scotland says no to Daiichi Sankyo’s cholesterol drug NilemdoThe Scottish Medicines Consortium (SMC) has rejected Daiichi Sankyo’s new cholesterol-lowering drug Nilemdo for use by NHS Scotland, Share XScotland says no to Daiichi Sankyo’s cholesterol drug Nilemdohttps://pharmaphorum.com/news/scotland-says-no-to-daiichi-sankyos-cholesterol-drug-nilemdo/
AstraZeneca sells rights to cholesterol drug Crestor to GrunenthalAstraZeneca is to sell European rights to its cholesterol drug Crestor (rosuvastatin) to Germany’s Grunenthal. Crestor is a Share XAstraZeneca sells rights to cholesterol drug Crestor to Grunenthalhttps://pharmaphorum.com/news/astrazeneca-sells-rights-to-cholesterol-drug-crestor-to-grunenthal/
Novartis’ big bet on inclisiran nears fruition, as CHMP backs drugNovartis’ near-$10 billion takeover of The Medicines Company last year was focused mainly on one asset – cholesterol-lowering Share XNovartis’ big bet on inclisiran nears fruition, as CHMP backs drughttps://pharmaphorum.com/news/novartis-big-bet-on-inclisiran-nears-fruition-as-chmp-backs-drug/
AZ buys oral PCSK9 cholesterol drug from Dogma TherapeuticsAstraZeneca has bought rights to an orally-active drug that inhibits PCSK9, offering a patient-friendly alternative to current cholesterol-lowering Share XAZ buys oral PCSK9 cholesterol drug from Dogma Therapeuticshttps://pharmaphorum.com/news/az-buys-oral-pcsk9-cholesterol-drug-from-dogma-therapeutics/
Novartis strikes landmark deal with NHS to speed up inclisiran accessNovartis and NHS England have forged a pact to accelerate the access of its new cholesterol-lowering drug inclisiran Share XNovartis strikes landmark deal with NHS to speed up inclisiran accesshttps://pharmaphorum.com/news/novartis-strikes-landmark-deal-with-nhs-to-speed-up-inclisiran-access/
Amgen pulls higher-priced Repatha to try to lift salesMore than four years after Amgen’s cholesterol-lowering antibody Repatha was approved in the US, the company still can’t Share XAmgen pulls higher-priced Repatha to try to lift saleshttps://pharmaphorum.com/news/amgen-pulls-higher-priced-repatha-to-try-to-lift-sales/
TMC’s inclisiran impresses at ESC, but will it surpass PCSK9 rivals?Cardiologists only had to wait a few days after The Medicines Company teased top-line results with its cholesterol-lowering Share XTMC’s inclisiran impresses at ESC, but will it surpass PCSK9 rivals?https://pharmaphorum.com/news/tmcs-inclisiran-impresses-at-esc-but-will-it-surpass-pcsk9-rivals/
TMC inches closer to inclisiran approval with long-term safety dataThe Medicines Company (TMC) has bet the proverbial farm on cholesterol-lowering candidate inclisiran and is celebrating new safety Share XTMC inches closer to inclisiran approval with long-term safety datahttps://pharmaphorum.com/news/tmc-inches-closer-to-inclisiran-approval-with-long-term-safety-data/
